Hemogenyx Pharmaceuticals (LON:HEMO) Shares Down 0.7% – Should You Sell?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) was down 0.7% during trading on Friday . The stock traded as low as GBX 572 and last traded at GBX 596. Approximately 985 shares changed hands during trading, a decline of 98% from the average daily volume of 60,595 shares. The stock had previously closed at GBX 600.

Hemogenyx Pharmaceuticals Price Performance

The company has a quick ratio of 6.72, a current ratio of 4.38 and a debt-to-equity ratio of 90.87. The stock’s 50 day moving average price is GBX 747.37 and its two-hundred day moving average price is GBX 598.91. The stock has a market cap of £35.27 million, a price-to-earnings ratio of -2.58 and a beta of 3.14.

Hemogenyx Pharmaceuticals (LON:HEMO) last posted its quarterly earnings results on Tuesday, September 30th. The company reported GBX (0.83) EPS for the quarter.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.